Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET).

@article{Kaiser2005IncrementalCO,
  title={Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivit{\"a}ts Trial (BASKET).},
  author={Christoph Kaiser and Hans Peter Brunner-La Rocca and Peter Buser and Piero Ovidio Bonetti and Stefan O\sswald and Andre Z. Linka and Alain Bernheim and Andreas W Zutter and Michael J Zellweger and Leticia Grize and Matthias Emil Pfisterer},
  journal={Lancet},
  year={2005},
  volume={366 9489},
  pages={921-9}
}
BACKGROUND No prospective trial-based data are available for incremental cost-effectiveness of drug-eluting stents (DES) compared with bare-metal stents (BMS) in unselected patients, as treated in everyday practice. METHODS The Basel stent cost-effectiveness trial (BASKET) included 826 consecutive patients treated with angioplasty and stenting for 1281 de-novo lesions, irrespective of indication for angioplasty. Patients were randomised to one of two DES (Cypher, n=264; Taxus, n=281) or to a… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 111 extracted citations

Similar Papers

Loading similar papers…